Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.
Tetsuji MoriyaMasatsugu HamajiAkihiko YoshizawaRyo MiyataMisa NoguchiShigeyuki TamariNaohisa ChibaHideaki MiyamotoToshiya ToyazakiSatona TanakaYoshito YamadaYojiro YutakaDaisuke NakajimaAkihiro OhsumiToshi MenjuHiroshi DatePublished in: Interactive cardiovascular and thoracic surgery (2021)
EGFR-TKIs as first-line treatment appeared to be a reasonable treatment option in selected patients with postoperative recurrent EGFR-mutated NSCLC. Osimertinib and the micropapillary component may be prognostic factors.